Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz <i>et al</i>

Mora, Jaume; Chantada, Guillermo

doi:10.1136/jitc-2021-003751

Cited by 2 publications

(2 citation statements)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В доклинических исследованиях in vitro и in vivo как ГМ-КСФ, так и Г-КСФ-стимулированные нейтрофилы опосредовали сопоставимый трогоцитоз опухолевого материала, что характеризует Г-КСФ как сопоставимое по эффективности лейкопоэтическое средство, обладающее меньшим профилем побочных эффектов, подлежащее к применению в планировании режимов ХИТ на основе GD2-специфических мАт. Необходимо отметить, что данная точка зрения оспаривается рядом авторов [49].…”

Section: Note It -The Regimen Of Chemotherapy With the Use Of Irinote...unclassified

Neuroblastoma chemoimmunotherapy: current results and application prospects

Ivanov

Kachanov

Shamanskaya

2023

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common extracranial solid tumor of childhood affecting children from 0 to 14 years old. Despite the achievements of modern multimodal risk-adapted therapy, the prognosis in patients with high-risk NB remains unfavorable. Numerous research groups have shown that a good response achieved at the time of completion of the induction stage of therapy in this subgroup of patients correlates with survival rates. Thus, improving the response to induction therapy may be a potential mechanism for improving long-term survival rates. Over the past few decades, traditional approaches to cancer therapy have undergone a radical revolution, largely due to the development and implementation of the immunotherapy method. It is known that combined antitumor therapy is superior to monotherapy and is one of the tools for overcoming heterogeneous drug resistance. A vast number of preclinical studies has shown that GD2-directed monoclonal antibodies (mAbs) are able to enhance the cytostatic effects of chemotherapeutic drugs, which has become a promising model for clinical studies of various chemoimmunotherapy regimens, which have demonstrated convincing evidence of safety and an acceptable toxicity profile with an encouraging effect on objective response rates, overall and event-free survival in both patients with recurrent, refractory NB, and primary patients of the high-risk group.The article discusses fundamental ideas about the synergistic interaction of GD2-directed mAbs in combination with cytostatic agents, the role of response to the induction stage of therapy and prospects for the use of induction chemoimmunotherapy as a method of improving postinduction response, event-free and overall survival in patients with NB.

show abstract

Section: Note It -The Regimen Of Chemotherapy With the Use Of Irinote...unclassified

Neuroblastoma chemoimmunotherapy: current results and application prospects

Ivanov

Kachanov

Shamanskaya

2023

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

show abstract

“…We appreciate the interest of Dr Mora and Dr Chantada 1 in our recently published work proposing granulocyte colony-stimulating factor (G-CSF) as a suitable alternative to improve antibody treatment of patients with high-risk neuroblastoma. 2 The authors strongly advocate finding ways to increase accessibility of granulocyte-monocyte colony-stimulating factor (GM-CSF, sargramostim), used in combination with dinutuximab in North America, also in countries where this treatment is currently not available.…”

mentioning

confidence: 99%